Collaborations Pharmaceuticals, Inc, 840 Main Campus Drive, Lab 3510, Raleigh, NC 27606, USA.
Department of War Studies and Department of Global Health & Social Medicine, King's College London, United Kingdom.
Drug Discov Today. 2023 Jan;28(1):103410. doi: 10.1016/j.drudis.2022.103410. Epub 2022 Oct 18.
Following a proof-of-concept presentation on dual-use artificial intelligence (AI) in drug discovery by Collaborations Pharmaceuticals Inc. to the Swiss Federal Institute for NBC-Protection, we explored how a generative algorithm could develop the nerve agent VX and tens of thousands of analogs in a highly impactful commentary. We not only laid out the experiment, but, with guidance from experts on arms control and dual-use, we called for more discussion around the general repurposing potential of AI in drug discovery. To continue that conversation, we now share further details on the experiment and place our experiences in the larger frame of other scientists who have similarly developed powerful technologies but without engaging with, or even truly understanding, the misuse potential and downstream consequences of the technologies. It is our sincere hope that our experiment may serve as an important wake-up call for users of generative AI.
在 Collaborations Pharmaceuticals Inc. 向瑞士联邦 NBC 保护研究所展示了药物发现中的两用人工智能 (AI) 的概念验证之后,我们探讨了生成算法如何在一篇极具影响力的评论中开发神经毒剂 VX 及其数万个类似物。我们不仅阐述了实验,而且在军备控制和两用专家的指导下,呼吁就人工智能在药物发现中的广泛重新应用潜力展开更多讨论。为了继续这一对话,我们现在分享更多关于该实验的细节,并将我们的经验置于其他同样开发了强大技术但没有参与甚至真正理解技术的滥用潜力和下游后果的科学家的更大框架内。我们真诚地希望我们的实验可以为生成人工智能的用户敲响警钟。